Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Pyridone ACAT inhibitors in development at Sumitomo

Nov. 10, 1999

Japanese researchers present new protein-tyrosine-phosphatase inhibitors

Nov. 10, 1999

Amylin successfully completes pivotal trials of Symlin; filings scheduled for mid-2000

Nov. 9, 1999

BioTime files for Canadian regulatory approval of Hextend

Nov. 9, 1999

Amgen presents promising phase III results for NESP at ASN

Nov. 9, 1999

Abbott enters diabetes collaboration with Karo Bio

Nov. 9, 1999

Landmark study in type II diabetics assesses long-term efficacy of Avandia

Nov. 8, 1999

Amgen's epoetin alfa approved in children with chronic renal failure

Nov. 8, 1999

Azacycloalkane derivatives from Sanofi-Synthelabo with dual hypoglycemic/antiinflammatory actions

Nov. 8, 1999

Merck's new antidiabetic agents modulate insulin receptor tyrosine kinase activity

Nov. 4, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...